Delayed Nausea and Vomiting in Patients With Colorectal Cancer Receiving Oxaliplatin
| Status: | Completed |
|---|---|
| Conditions: | Colorectal Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | June 2005 |
| End Date: | December 2008 |
Prevalence of Delayed Nausea and Vomiting in Patients Being Treated With Oxaliplatin-based Regimens (mFOLFOX6 or FOLFOX7) for Colorectal Cancer
RATIONALE: Learning how often patients experience nausea and vomiting after receiving
anti-vomiting medicine and chemotherapy for colorectal cancer may help doctors plan better
treatment and improve patients' quality of life.
PURPOSE: This clinical trial is studying delayed nausea and vomiting in patients with
colorectal cancer receiving standard anti-vomiting medicine during the first course of
chemotherapy.
anti-vomiting medicine and chemotherapy for colorectal cancer may help doctors plan better
treatment and improve patients' quality of life.
PURPOSE: This clinical trial is studying delayed nausea and vomiting in patients with
colorectal cancer receiving standard anti-vomiting medicine during the first course of
chemotherapy.
OBJECTIVES:
- To assess the prevalence of delayed nausea and vomiting in patients with colorectal
cancer receiving standard anti-emetic medications during the first course of an
oxaliplatin-based chemotherapy regimen (mFOLFOX6 or FOLFOX7).
OUTLINE: This is a multicenter study.
Patients undergo collection of demographic, diagnostic, and treatment data at baseline.
Patients complete the Functional Living Index-Emesis (FLIE) questionnaire at baseline prior
to first chemotherapy infusion and at 5-7 days. Patients also fill out daily patient diaries
about symptoms of nausea and vomiting, and use of medications to prevent these symptoms over
days 1-5.
- To assess the prevalence of delayed nausea and vomiting in patients with colorectal
cancer receiving standard anti-emetic medications during the first course of an
oxaliplatin-based chemotherapy regimen (mFOLFOX6 or FOLFOX7).
OUTLINE: This is a multicenter study.
Patients undergo collection of demographic, diagnostic, and treatment data at baseline.
Patients complete the Functional Living Index-Emesis (FLIE) questionnaire at baseline prior
to first chemotherapy infusion and at 5-7 days. Patients also fill out daily patient diaries
about symptoms of nausea and vomiting, and use of medications to prevent these symptoms over
days 1-5.
DISEASE CHARACTERISTICS:
- Diagnosis of colorectal cancer
- Currently receiving OR scheduled to receive the first course of either of the
following chemotherapy regimens:
- mFOLFOX6
- FOLFOX7
- No clinical or imaging evidence of brain metastasis
PATIENT CHARACTERISTICS:
- Able to maintain a diary and complete a standardized quality of life questionnaire in
English
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- More than 90 days since prior aprepitant
We found this trial at
1
site
Click here to add this to my saved trials
